LB Pharmaceuticals Inc
corporate_fare Company Profile
LB Pharmaceuticals Inc (NASDAQ:LBRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for LBRX at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- LB Pharmaceuticals Appoints Neuroscience R&D Veteran Robert Lenz to Board, Promotes Gad Soffer to COO
- Deep Track Capital Increases Stake to 11.7% in LB Pharmaceuticals via Private Placement
- 10% Owner Deep Track Capital Buys $10M in Pre-Funded Warrants Following Private Placement
- Secures $100M Private Placement to Fund Phase 2 MDD Trial for LB-102
Financial Snapshot
Fiscal year ended December 31, 2025
Net Income
-$25.2M
Diluted EPS
-$3.13
Op. Cash Flow
-$35.21M
Free Cash Flow
-$35.26M
Cash & Equivalents
$250.17M
Debt / Equity
0.00×
Shares Outstanding
25.3M sh
Source: 10-K · filed 2026-03-26 · accession 0001193125-26-126368
show_chartPrice Chart
Loading chart...
feed LBRX - Filings & News (Page 2)
LBRX
Mar 10, 2026, 8:15 AM EDT
Price at Filing:
$24.34
Real-time Price:
$38.85
Change:
+$14.51 (+60%)
Market Cap:
$1.257B
LBRX
Feb 10, 2026, 4:30 PM EST
Price at Filing:
$24.22
Real-time Price:
$38.85
Change:
+$14.63 (+60%)
Market Cap:
$1.257B
LBRX
Feb 10, 2026, 4:30 PM EST
Price at Filing:
$24.22
Real-time Price:
$38.85
Change:
+$14.63 (+60%)
Market Cap:
$1.257B
LBRX
Feb 05, 2026, 8:15 AM EST
Price at Filing:
$22.35
Real-time Price:
$38.85
Change:
+$16.50 (+74%)
Market Cap:
$1.257B